Form 4: Teladoc Health Executive Andrew Turitz Sells Shares Under 10b5-1 Trading Plan

Andrew Turitz, EVP of Corporate Development at Teladoc Health, sold 5,647 shares of common stock at $14.53 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 5, 2024, Andrew Turitz, the EVP of Corporate Development at Teladoc Health, sold 5,647 shares of the company's common stock.
• The sale was executed at a price of $14.53 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted by Turitz on November 27, 2023.
• Following the transaction, Turitz directly owns 33,782 shares of Teladoc Health.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an executive's stock sale. The sale was conducted under a pre-arranged trading plan, suggesting it's not necessarily indicative of the executive's sentiment towards the company's prospects. Therefore, the sentiment is neutral.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of 10b5-1 trading plans allows insiders to sell shares at predetermined times and prices, avoiding accusations of insider trading. Investors often monitor these transactions for insights into management's perspective on the company's future prospects, although sales under 10b5-1 plans are typically less informative than discretionary trades.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 trading plan mitigates this concern.

Key Dates